Page 1

++ adapthealth FOR IMMEDIATE RELEASE ADAPTHEALTH ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS , RAISES FULL - YEAR 2021 GUIDANCE , AND PROVIDES FULL - YEAR 2022 GUIDANCE Plymouth Meeting , PA - November 4 , 2021 - AdaptHealth Corp. ( NASDAQ : AHCO ) ( " AdaptHealth " or " the Company " ) , a national leader in providing patient - centered , healthcare - at - home solutions including home medical equipment , medical supplies , and related services , announced today financial results for the third quarter ended September 30 , 2021 . Highlights • AdaptHealth delivered record net revenue and Adjusted EBITDA for the third quarter and further increased fiscal 2021 guidance , despite the challenging operating environment . • During the quarter , the Company completed six previously - discussed acquisitions , expanding HME operations in Kentucky , Ohio , West Virginia , New Jersey , New York , South Carolina , and Florida . • • Since quarter end , the Company has completed four additional acquisitions : three HME providers in Florida , Washington , and Wisconsin , and a diabetes supplier in Texas . In addition to the AeroCare merger , AdaptHealth has acquired more than $ 400 million in annualized revenue to date in 2021 . In August the Company completed an offering of $ 600 million aggregate principal amount of 5.125 % unsecured senior notes due 2030 . Third Quarter Results • Net revenue was $ 653.3 million , compared to $ 284.4 million in the third quarter of 2020 , a 130 % increase . • Organic growth for the third quarter was 6.5 % . • • • Net income attributable to AdaptHealth Corp. was $ 58.1 million , or $ 0.20 per diluted share , compared to a net loss of $ 51.0 million , or $ 0.89 per diluted share , in the third quarter of 2020 . Adjusted EBITDA was $ 156.3 million , compared to $ 53.2 million in the third quarter of 2020 , a 194 % increase . Adjusted EBITDA less Patient Equipment Capex was $ 106.1 million , compared to $ 35.9 million in the third quarter of 2020 , a 196 % increase . Guidance Increased for 2021 Based on current business , market trends , and acquisitions completed to date , the Company is increasing its previously issued financial guidance for fiscal year 2021 as follows : • • • Net revenue of $ 2.41 billion to $ 2.46 billion , up from prior guidance of $ 2.38 billion to $ 2.48 billion ; Adjusted EBITDA of $ 570 million to $ 580 million , up from prior guidance of $ 555 million to $ 580 million ; and Adjusted EBITDA less Patient Equipment Capex of $ 365 million to $ 375 million , up from prior guidance of $ 360 million to $ 375 million .